Whole exome sequencing reveals novel somatic alterations in neuroblastoma patients with chemotherapy
Open Access
- 17 February 2018
- journal article
- research article
- Published by Springer Nature in Cancer Cell International
- Vol. 18 (1) , 21
Abstract
We ought to explore the acquired somatic alterations, shedding light on genetic basis of somatic alterations in NB patients with chemotherapy. Marrow blood samples from NB patients were collected before treatment, after the 2nd and 4th chemotherapy for baseline research and continuous monitoring by whole exome sequencing. Plasma cell free DNA (cfDNA) was prepared for baseline research. Finger nail cells were extracted as self control. The clinical data was analyzed. From December 2014 to February 2016, 27 cases of children with stage IV NB were diagnosed. The follow up time ranged from 5 to 25 months, with a median follow up time of 17 months, 20 patients were stable, one patient died of pulmonary embolism during surgery, six patients died of disease progression. Marrow blood whole exome sequencing demonstrated that several novel somatic mutations were identified in all three trios comply or against the trendy of tumor size variation. Of note, six recurrent mutations in bromodomain PHD finger transcription factor (BPTF) were identified in nine NB patients under the continuous monitoring. The mutation rates variation was positively correlated to tumor size (CC = 0.428, P = 0.021), and patients with BPTF mutation may have a worse prognosis compared with wild type. Meanwhile, CGREF1, CUX2, GP1BA, SLC45A1 and TRA2A were mutated with the trendy oppose as therapeutic effects. The baseline research in three NB patients demonstrated that mutation rate of BPTF, TMCO3, GPRIN2 and C20orf96 in plasma cfDNA were in positive correlation with bone marrow genomic DNA (P = 0.001). Our study showed that BPTF along with other mutations may function as a biomarker for evaluating to effects of chemotherapy to this refractory tumor, and patients with BPTF mutation might have a worse prognosis.Keywords
Funding Information
- Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park (Z151100004015159)
This publication has 14 references indexed in Scilit:
- MYCN amplification predicts poor prognosis based on interphase fluorescence in situ hybridization analysis of bone marrow cells in bone marrow metastases of neuroblastomaCancer Cell International, 2017
- Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterationsCancer, 2015
- BPTF promotes tumor growth and predicts poor prognosis in lung adenocarcinomasOncotarget, 2015
- The Chromatin Remodeling Protein Bptf Promotes Posterior Neuroectodermal Fate by Enhancing Smad2-Activatedwnt8aExpressionJournal of Neuroscience, 2015
- The Genetics of Splicing in NeuroblastomaCancer Discovery, 2015
- The prognostic significance of bromodomain PHD-finger transcription factor in colorectal carcinoma and association with vimentin and E-cadherinJournal of Cancer Research and Clinical Oncology, 2015
- BPTF Associated with EMT Indicates Negative Prognosis in Patients with Hepatocellular CarcinomaDigestive Diseases and Sciences, 2014
- The genetic landscape of high-risk neuroblastomaNature Genetics, 2013
- Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastomaNature Genetics, 2012
- Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patternsBlood, 2012